Regemat 3D opens a round of €3 million through crowdfunding

The health sector continues to be attractive to investors despite the coronavirus health emergency, and the bioprinting market is another example. Regemat 3D, a company from Granada specialized in the generation of three-dimensional tissues, will open in the next few days a financing round through the crowdfunding platform Crowdcube with which it expects to raise $3.47 million (€3 million), according to the company’s explanation. 

“In the coming days, Regemat 3D will allow the entry of equity to all types of investors, through a round of crowdfunding, something that had been in demand in the sector,” advanced from the company. Regemat 3D hopes to use the resources to continue its international activity and add new suppliers and users on a global scale. 

At the moment, the company exports its bioprinting systems and bioreactors to 28 different countries, according to information provided by Regemat 3D. Likewise, it has already obtained $809,000 (€700,000) this year between the ICO funds, the Cervera de Cdti instrument and the H2020 program. 

Read more details about the bioprinting market and the crowdfunding campaign Regemat 3D wants to launch with our companion app. Born2Invest brings you the most important financial headlines for you to stay informed.

Regemat 3D started the year with the launch of its new bioprinting system, the REG4Life

Regemat 3D bioprinter is one of the main players in the sector for having developed a three-dimensional tissue generation process. First the three-dimensional construct is printed, which is then matured in a bioreactor where, after the application of a series of mechanobiological signals, the generation of a functional tissue is favored. 

The company makes its technology available to research groups from various scientific areas to develop these tissues by combining cells, biomaterials, and other biomolecules in order to reproduce the three-dimensionality of any tissue. Regemat 3D also offers its bioreactors to mature the tissues (marketed under its Bmap brand) and the necessary fungible materials to carry out the process. 

In addition to the Bmap line of bioreactors, the company started the year with the launch of its new bio-printing system, the REG4Life bioprinter, which represents the implementation of advances and improvements compared to the first version of the device that has been on the market for more than three years.  

The three-dimensional bioprinting market will exceed $1.6 billion in four years 

Regemat 3D was founded in 2015 and is located in the Granada Health Technology Park. The company was born out of another company, Breca Health Care, which was founded in 2011 and specializes in 3D printing of medical devices. Regemat 3D emerges as a project focused on cartilage cells. 

The 3D bioprinting market will reach a value of $1.65 billion in 2024, according to a study by Markets and Markets. The large number of tissue pathologies derived from aging and the need to accelerate the times in the development of new drugs and reduce the use of animals for research makes 3D bioprinting a sector that is gaining a lot of interest in the research and scientific field.

__

(Featured image by Edward Jenner via Pexels)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.